Researchers stratified a dataset of more than 100 patients in an emergency department to see which patients may be indicated for retinal artery occlusions.

In a now-deleted TikTok that raked in millions of views, Esther Jeong, from California, explained that she was recently ...

for aflibercept injection 8mg for the treatment of macular edema following retinal vein occlusion (RVO) and monthly dosing across all approved indications. The sBLA was supported by data from the ...

The prevalence of central RVO ranges from 0.1% to 0.2% of the global population, while branch RVO affects anywhere from 0.5% to 2% of the population. 3 “With these pivotal results in retinal vein ...

There are two main types of RVO: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). In CRVO, the buildup occurs in the eye’s central retinal vein and in BRVO ...

Acute ischemic stroke (AIS) is the leading cause of adult disability in the United States and a major cause of death both ...

There two types of RAOs: Branch retinal artery occlusion (BRAO): This blocks the small arteries in the retina. Central retinal artery occlusion (CRAO): This is a blockage in the central artery in ...

There are two main types of retinal vein occlusion: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). In CRVO, the buildup occurs in the eye’s central retinal vein, and ...

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.

2 Previous reporting from the QUASAR trial 3 indicated aflibercept 8 mg results were consistent across patients with branch RVOs, and those patients with central retinal or hemiretinal vein occlusions ...

for the treatment of patients with macular edema following retinal vein occlusion (RVO) including central, branch and hemiretinal vein occlusion. This would be the third indication for aflibercept 8 ...